Therapeutic Advances in Childhood Leukemia Consortium
Therapeutic Advances in Childhood Leukemia Consortium
Explore linked clinical trials.5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia | CBL-related disorder, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, bone marrow disorder, hematologic disorder, hereditary disease, hereditary neoplastic syndrome, inherited neurodegenerative disorder, juvenile myelomonocytic leukemia, leukemia, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, nerve sheath neoplasm, nervous system disorder, neurocutaneous syndrome, neurodegenerative disease, neurofibroma, neurofibromatosis, neurofibromatosis type 1, neuromuscular disease, peripheral nervous system disorder | Recruiting | Phase 1 / Phase 2 | 2026-09-04 | NCT05849662 | |
| Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL | B-cell acute lymphoblastic leukemia, B-cell neoplasm, Body Weight, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Leukemia, B-Cell, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Pediatric Obesity, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Signs and Symptoms, Tumor Virus Infections, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, nutritional disorder, obesity disorder, overnutrition, viral infectious disease | Recruiting | Phase 2 | 2026-08-19 | NCT05082519 | |
| Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML." | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Phase 2 | 2026-07-22 | NCT07686107 | |
| PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | Hemic and Lymphatic Diseases, Leukemia, Lymphocytic, Acute, L1, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2025-06-17 | NCT03817320 | |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | B-cell neoplasm, CD4+/CD56+ hematodermic neoplasm, Hemic and Lymphatic Diseases, Hodgkins lymphoma, Neoplasms by Histologic Type, Neoplasms by Site, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Skin and Connective Tissue Diseases, T-cell non-Hodgkin lymphoma, acute biphenotypic leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, acute undifferentiated leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mixed phenotype acute leukemia, myelodysplastic syndrome, neoplasm, skin disorder, skin neoplasm | Recruiting | Phase 1 | 2024-12-06 | NCT05476770 |